Afya (NASDAQ:AFYA – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of $0.4054 per share and revenue of $190.5110 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.
Afya Price Performance
NASDAQ:AFYA opened at $13.94 on Wednesday. The company has a market cap of $1.31 billion, a P/E ratio of 9.11, a P/E/G ratio of 1.41 and a beta of 0.34. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.78 and a current ratio of 1.78. Afya has a 52-week low of $13.00 and a 52-week high of $16.50. The stock’s 50-day simple moving average is $14.35 and its 200 day simple moving average is $14.44.
Insiders Place Their Bets
In related news, VP Gomiero Mirella Basolli sold 10,000 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $14.80, for a total value of $148,000.00. Following the transaction, the vice president owned 34,530 shares in the company, valued at approximately $511,044. This trade represents a 22.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Lelio De Souza Junior sold 41,541 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $15.00, for a total value of $623,115.00. Following the completion of the transaction, the vice president directly owned 36,204 shares of the company’s stock, valued at approximately $543,060. This trade represents a 53.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 87,745 shares of company stock worth $1,314,175 in the last 90 days.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several research analysts have recently commented on AFYA shares. Wall Street Zen downgraded Afya from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings downgraded Afya from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday. JPMorgan Chase & Co. reduced their price objective on shares of Afya from $21.50 to $21.00 and set a “neutral” rating for the company in a research report on Monday, June 22nd. Bank of America reiterated a “neutral” rating on shares of Afya in a report on Thursday, June 11th. Finally, Zacks Research cut shares of Afya from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Afya presently has an average rating of “Hold” and a consensus target price of $17.88.
Read Our Latest Analysis on AFYA
Afya Company Profile
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Featured Articles
- Five stocks we like better than Afya
- Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
